The current literature to investigate the challenges malaria vaccination faced in reaching high-risk children.
Novel Combination Boosts Survival in Unresectable Liver Cancer
The PD-1 inhibitor camrelizumab combined with the VEGFR2-targeted inhibitor rivoceranib (also known as apatinib) significantly improved survival compared with sorafenib (Nexavar) alone for the treatment